Teacher Retirement System of Texas Has $1.31 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Teacher Retirement System of Texas grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 18.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 43,565 shares of the biopharmaceutical company’s stock after buying an additional 6,742 shares during the quarter. Teacher Retirement System of Texas’ holdings in TG Therapeutics were worth $1,311,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Xponance Inc. boosted its stake in TG Therapeutics by 14.7% in the 4th quarter. Xponance Inc. now owns 10,318 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 1,326 shares during the period. Cibc World Markets Corp acquired a new position in shares of TG Therapeutics during the fourth quarter worth about $393,000. GWN Securities Inc. bought a new position in shares of TG Therapeutics during the fourth quarter worth about $395,000. Envestnet Portfolio Solutions Inc. bought a new position in shares of TG Therapeutics during the fourth quarter worth about $216,000. Finally, Natixis Advisors LLC bought a new stake in TG Therapeutics in the 4th quarter valued at approximately $857,000. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TGTX shares. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Price Performance

Shares of TGTX opened at $39.86 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company’s fifty day simple moving average is $34.37 and its 200 day simple moving average is $30.29. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32. The company has a market cap of $6.26 billion, a price-to-earnings ratio of -398.56 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.